Clinical Trials · NCT00658021
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 122
- Start date
- May 2008
- Locations
- 53 sites, 8 countries
- Primary endpoint
- Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28